Prognosis and treatment of Vernal keratoconjunctivitis in pediatric age: Pilot study on 197 patients;Prognosi e trattamento della cheratocongiuntivite Vernal in età pediatrica: Studio pilota su 197 pazienti

Minerva Pediatrica

Volumn 62, Issue 3, 2010, Pages 239-244

  Spadavecchia, L ^a   Fanelli, P ^a   Tesse, R ^a   Rizzo, G ^a   Procoli, U ^a   Bellizzi, M ^a   Armenio, L ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Child; Conjunctivitis; Cyclosporine

Indexed keywords

CYCLOSPORIN; CYCLOSPORIN A; IMMUNOGLOBULIN E; IMMUNOSUPPRESSIVE AGENT;

ADOLESCENT; ARTICLE; CELL DAMAGE; CHILD; CHILDHOOD DISEASE; CORNEA CELL; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; ENDOTHELIUM CELL; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MICROSCOPY; PILOT STUDY; PRESCHOOL CHILD; PRICK TEST; PROGNOSIS; SCHOOL CHILD; SCORING SYSTEM; SYMPTOM; TREATMENT RESPONSE; VERNAL CONJUNCTIVITIS; CLINICAL TRIAL; CONJUNCTIVITIS, ALLERGIC;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CONJUNCTIVITIS, ALLERGIC; CYCLOSPORINE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; PILOT PROJECTS; PROGNOSIS;

EID: 77955402559     PISSN: 00264946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Bonini S, Coassin M, Aronni S, Lambiase A. Vernal keratoconjunctivitis. Eye 2004;18:345-51.
2. Baudouin C, Liang H, Bremond-Gignac D, Hamard P, Hreiche R, Creuzot-Garcher C et al. CCR 4 and CCR 5 expression in conjunctival specimens as differential markers of T(H)1/ T(H)2 in ocular surface disorders. J Allergy Clin Immunol 2005;116:614-9. (Pubitemid 41267136)
3. Leonarda A, DeFranchis G, Zancanaro F, Crivellari G, De Paoli M, Plebani M et al. Identification of local Th2 and ThO lymphocytes in vernal conjunctivitis by cytokine flow cytometry. Invest Ophthalmol Vis Sci 1999;40:3036-40. (Pubitemid 29521623)
4. Anderson DF, Zhang S, Bradding P, McGill JI, Holgate ST, Roche WR. The relative contribution of mast cell subsets to conjunctival TH2-like cytokines. Invest Ophthalmol Vis Sci 2001;42:995-1001. (Pubitemid 32289795)
5. Leonardi A, Borghesan F, Faggian D, Secchi A, Plebani M. Eosinophil cationic protein in tears of normal subjects and patients affected by vernal keratoconjunctivitis. Allergy 1995;50:610-3.
6. Uchio E, Ono SY, Ikezawa Z, Ohno S. Tear levels of interferon-gamma, interleukin (IL) -2, IL-4 and IL-5 in patients with vernal keratoconjunctivitis, atopic keratoconjunctivitis and allergic conjunctivitis. Clin Exp Allergy 2000;30:103-9. (Pubitemid 30093887)
7. Spadavecchia L, Fanelli P, Tesse R, Brunetti L, Cardinale F, Bellizzi M et al. Efficacy of 1.25% and 1% topical cyclosporine in the treatment of severe vernal keratoconjunctivitis in childhood. Pediatr Allergy Immunol 2006;17:527-32. (Pubitemid 44511088)
8. Pucci N, Novembre E, Lombardi E, Cianferoni A, Bernardini R, Massai C et al. Atopy and serum eosinophil cationic protein in 110 white children with Vernal Keratoconjunctivitis: differences between tarsal and limbal forms. Clin Exp Allergy 2003;33:325-30. (Pubitemid 36315173)
9. Montan PG, Ekstrom K, Hedlin G, van Hage-Hamsten M, Hjern A, Herrmann B. Vernal keratoconjunctivitis in a Stockholm ophthalmic centre-epidemiological, functional, and immunologic investigations. Acta Ophthalmol Scand 1999;77:559-63. (Pubitemid 29476377)
10. Bonini S. Atopic keratoconjunctivitis. Allergy 2004;59:71-3.
11. Avunduk AM, Avunduk MC, Kapicioglu Z, Akyol N, Tavli L. Mechanisms and comparison of anti-allergic efficacy of topical lodoxamide and cromolyn sodium treatment in vernal keratoconjunctivitis. Ophthalmology 2000;107:1333-7.
12. Berdy GJ. The effects of systemic medication on ocular allergic disease. Acta Ophthalmol Scand Suppl 2000;(230):26-31.
13. Verin P, Allewaert R, Joyaux JC, Piozzi E, Koliopoulos J, Bloch-Michel E; Lodoxamide Study Group. Comparison of lodoxamide 0.1% ophthalmic solution and levocabastine 0.05% ophthalmic suspension in vernal keratoconjunctivitis. Eur J Ophthalmol 2001;11:120-5.
14. Lisanework M. Supra-tarsal injection of dexamethasone in the treatment of patients with refractory vernal keratoconjunctivitis. Ethiop Med J 2003;41:19-24. (Pubitemid 44807518)
15. Pucci N, Novembre E, Cianferoni A, Lombardi E, Bernardini R, Caputo R et al. Efficacy and safety of cyclosporine eyedrops in vernal keratoconjunctivitis. Ann Allergy Asthma Immunol 2002;89:298-303.
16. Gupta V, Sahu PK. Topical cyclosporin A in the management of vernal keratoconjunctivitis. Eye 2001;15:39-41. (Pubitemid 32258214)
17. Kiliç A, Gürler B. Topical 2% cyclosporine A in preservative-free artificial tears for the treatment of vernal keratoconjunctivitis. Can J Ophthalmol 2006;41:693-8. (Pubitemid 46113021)
18. Tomida I, Schlote T, Brauning J, Heide PE, Zierhut M. Cyclosporin A 2% eyedrops in therapy of atopic and vernal keratoconjunctivitis. Ophthalmologe 2002;99:761-7.
19. Kosrirukvongs P, Vichyanond P, Wongsawad W. Vernal keratoconjunctivitis in Thailand. Asian Pac J Allergy Immunol 2003;21:25-30.
20. Kosrirukvongs P, Luengchaichawange C. Topical cyclosporine 0.5 per cent and preservative-free ketorolac tromethamine 0.5 per cent in vernal keratoconjunctivitis. J Med Assoc Thai 2004;87:190-7. (Pubitemid 38470284)
21. Choi H, Lee SB. Nonseasonal allergic conjunctivitis in the tropics: experience in a tertiary care institution. Ocul Immunol Inflamm 2008;16:141-5.
22. Keklikci U, Soker SI, Sakalar YB, Unlu K, Ozekinci S, Tunik S. Efficacy of topical cyclosporin A 0.05% in conjunctival impression cytology specimens and clinical findings of severe vernal keratoconjunctivitis in children. Jpn J Ophthalmol 2008;52:357-62.
23. Ozcan AA, Ersoz TR, Dulger E. Management of severe allergic conjunctivitis with topical cyclosporin a 0.05% eyedrops. Cornea 2007;26:1035-8. (Pubitemid 47480680)
24. Murai H, Osoegawa M, Ochi H, Kira J. High frequency of allergic conjunctivitis in myasthenia gravis without thymoma. J Neurol Sci 2004;225:27-31. (Pubitemid 39311706)